The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28621538 |
63 |
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo. |
Novartis Pharma |
28157311 |
11 |
Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors. |
Novartis Institutes For Biomedical Research |
27994744 |
16 |
Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors. |
University of Michigan |
24900799 |
3 |
Inhibitors of factor d may provide a treatment for age-related macular degeneration. |
Therachem Research Medilab (India) |
24900375 |
4 |
Factor D Inhibitors for the Treatment of AMD: Patent Highlight. |
TBA |
32551603 |
185 |
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. |
Novartis Institutes For Biomedical Research |
32073845 |
74 |
Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases |
Novartis Institutes For Biomedical Research |
30995036 |
52 |
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway. |
Novartis Institutes For Biomedical Research |
30295487 |
18 |
Ligand-Based Fluorine NMR Screening: Principles and Applications in Drug Discovery Projects. |
Lavis |
28977749 |
75 |
Chemical Approaches to Modulating Complement-Mediated Diseases. |
The University of Queensland |
29795765 |
32 |
Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D. |
Novartis Pharma |
17539825 |
74 |
1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2. |
Chemdiv |
19703027 |
5 |
In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation. |
University of Jordan |
| 83 |
Thermodynamic and Nuclear Magnetic Resonance Study of the Interactions of alpha-and beta-Cyclodextrin with Model Substances: Phenethylamine, Ephedrines, and Related Substances |
Nist |
19645433 |
37 |
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. |
St. Jude Research Hospital |
17585749 |
56 |
Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides. |
Amgen |
7562908 |
46 |
Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. |
University of Auckland |
10508432 |
12 |
Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors. |
Uppsala University |